the changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 ›...
TRANSCRIPT
![Page 1: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/1.jpg)
1PAGE
The changing dynamics of the pharmaceutical industry
![Page 2: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/2.jpg)
2PAGE
Digital and technology innovation
Patient empowerment & stakeholder diversity
The biotech and pharma fields are geared to adapt to new market drivers*
Pricing and market access challenges, even in specialty and rare diseases
Patient
Patient services beyond the pill
Real-world evidence and artificial intelligence
1
2
3
45
* Non-exhaustive list.
![Page 3: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/3.jpg)
3PAGE
The HCP is no longer the sole decision maker
• Patients are more connected, informed and empowered to drive decisions
• A more complex ecosystem of stakeholders is centred around the patient
• Need to find way to connect with all stakeholders to ensure appropriate therapy use
1
![Page 4: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/4.jpg)
4PAGE
Growing patient demographics and Tx options drive price pressures
• Greater need for payers and prescribers to control product cost
• Rising cost of therapies becoming an issue even in specialty medicine and rare diseases
• Need to design and advocate for unique value and access approaches
2
![Page 5: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/5.jpg)
5PAGE
New technologies pave new avenues of interacting with customers
• New technologies offer support, connect the ecosystem, provide efficiencies and inform decision-making
• Need to overcome technology related limitations, and embrace new ways of delivering fast, relevant, appropriate information
3
![Page 6: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/6.jpg)
6PAGE
Patients are expecting more than just medicines
• Need for engagement across the patient journey
• Importance of exhibiting commitment to the therapy area and patient needs
• Need to provide beyond the pill support to patients
4
![Page 7: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/7.jpg)
7PAGE
Introduction of real-world evidence (RWE) and data
• HCPs, regulators and payers are seeking richer insights in real time
• RWE has changed the way data is captured and used
• Increased requirement to design better (faster, more informative) trials
• Need to extract and communicate insights from RWE and AI-based solutions
5
![Page 8: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/8.jpg)
8PAGE
Historically, changes in healthcare have impacted ways of working in the pharmaceutical industry
• As the industry is maturing over time, it became critical for key functions to get a more integral role
Need for higher level medical insights and
peer interactions
Greater stakeholder set and need to uphold
ethical standardClinical data
complexity and need for long-term insights
Pricing pressures and increasing role of
payers and regulators
Medical affairs
Market access & pricing
Pharmacovigilance
Medical affairs
Market access & pricing
Medical affairs
Pharmacovigilance
Market access & pricing
Medical affairs
Ethics & ComplianceProviding guidance on how to uphold an ethical standard, and offer solutions to
best adapt to the changing market environment
![Page 9: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/9.jpg)
9PAGEPAGE 9
Ethics & Compliance has matured and is now empowered to take a holistic viewpoint
• Fully integrated across all functions, beyond commercial including HR, IT and analytics
• Related to organisational culture
• Important to be at the forefront of business decisions
![Page 10: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/10.jpg)
10PAGE
What does this changing environment mean for the pharmaceutical industry?
![Page 11: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/11.jpg)
11PAGE
We need to manage risks and stay competitive
![Page 12: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/12.jpg)
12PAGE
By embedding Ethics & Compliance in our DNA as a business
![Page 13: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/13.jpg)
13PAGE
How can ethics and compliance roles complement the needs of the new business model?
Contribute to the brand strategies
Promote an ethical and compliant culture
Encourage cross-functional work
Collaborate with teams to clarify the rationale of activities
Integrate E&C in leadership teams
![Page 14: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/14.jpg)
14PAGE
With so many patients’ needs unmet, there is still much to be done
![Page 15: The changing dynamics of the pharmaceutical industry › presentations › intpharmacon13 › semerjian_1.pdfPatient empowerment & stakeholder diversity The biotech and pharma fields](https://reader033.vdocuments.us/reader033/viewer/2022060404/5f0f05347e708231d442175f/html5/thumbnails/15.jpg)
15PAGE
Thank you